Telomir Pharmaceuticals Inc (TELO)

$1.23 -0.03 (-2.38%)
Market Cap 44.35M
Revenue (ttm) 0.00
Net Income (ttm) -10.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,901
Avg Vol 143,612
Day's Range N/A - N/A
Shares Out 34.38M
Stochastic %K 8%
Beta -0.21
Analysts Strong Buy
Price Target $15.50

Company Profile

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Proge...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 396 6723
Address:
100 SE 2nd Street, Suite 2000 #1009, Miami, United States
PF_Goodrich
PF_Goodrich May. 12 at 6:03 PM
$TELO tempted to buy more at this price but I already bought a bunch at 1.28
0 · Reply
Tristan2024
Tristan2024 May. 12 at 12:28 PM
$TELO 🚀🚀🚀
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:28 AM
$TELO do it and surprise everyone
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:28 AM
$TELO not regretted buying it for a second
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:28 AM
$TELO we will do it...one of a kind drug
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:27 AM
$TELO 2.5>4>6.4>8$
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:27 AM
$TELO never lost hope in that
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:26 AM
$TELO news pending...watch the next jump to 2$
1 · Reply
Washingtonstate
Washingtonstate May. 9 at 1:46 AM
$TELO
1 · Reply
PF_Goodrich
PF_Goodrich May. 7 at 3:15 PM
$TELO come down to papa. my position is at 1.33 and im looking to build
0 · Reply
Latest News on TELO
Telomir announces U.S. FDA cleared IND application for Telomir-Zn

2026-04-30T15:55:48.000Z - 13 days ago

Telomir announces U.S. FDA cleared IND application for Telomir-Zn

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Apr 30, 2026, 8:00 AM EDT - 13 days ago

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Telomir Pharmaceuticals completes acquisition of TELI Pharmaceuticals

2026-04-24T13:09:45.000Z - 19 days ago

Telomir Pharmaceuticals completes acquisition of TELI Pharmaceuticals

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Apr 24, 2026, 9:00 AM EDT - 19 days ago

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC

2026-03-31T12:42:50.000Z - 6 weeks ago

Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC

Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC

2026-03-31T12:29:50.000Z - 6 weeks ago

Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

Telomir Pharmaceuticals announces in vitro data on Telomir-1

2026-02-17T13:46:33.000Z - 3 months ago

Telomir Pharmaceuticals announces in vitro data on Telomir-1

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Feb 17, 2026, 8:00 AM EST - 3 months ago

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Telomir Pharmaceuticals reports cellular study results on Telomir-1

2026-02-05T13:25:25.000Z - 3 months ago

Telomir Pharmaceuticals reports cellular study results on Telomir-1

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Feb 5, 2026, 8:00 AM EST - 3 months ago

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw

2026-01-13T20:20:48.000Z - 4 months ago

Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw

Telomir Pharmaceuticals reports results from efficacy study for Telomir-1

2026-01-05T14:35:51.000Z - 4 months ago

Telomir Pharmaceuticals reports results from efficacy study for Telomir-1

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Jan 5, 2026, 8:00 AM EST - 4 months ago

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Telomir Pharmaceuticals reports results from safety studies for Telomir-1

2025-12-18T12:45:18.000Z - 5 months ago

Telomir Pharmaceuticals reports results from safety studies for Telomir-1

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Dec 18, 2025, 7:30 AM EST - 5 months ago

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Telomir Pharmaceuticals announces new preclinical data on Telomir-1

2025-11-25T13:15:14.000Z - 6 months ago

Telomir Pharmaceuticals announces new preclinical data on Telomir-1

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Nov 25, 2025, 8:00 AM EST - 6 months ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Telomir Pharmaceuticals announces in vitro data on Telomir-1

2025-11-21T12:35:19.000Z - 6 months ago

Telomir Pharmaceuticals announces in vitro data on Telomir-1

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Nov 21, 2025, 7:30 AM EST - 6 months ago

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Telomir Pharmaceuticals announces new preclinical data on Telomir-1

2025-11-12T13:36:31.000Z - 6 months ago

Telomir Pharmaceuticals announces new preclinical data on Telomir-1

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

Nov 12, 2025, 8:00 AM EST - 6 months ago

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

Telomir says data shows Telomir-1 resets cancer ‘kill-and-clean’ defense system

2025-10-23T11:45:22.000Z - 7 months ago

Telomir says data shows Telomir-1 resets cancer ‘kill-and-clean’ defense system

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

Oct 23, 2025, 7:30 AM EDT - 7 months ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

Telomir Pharmaceuticals executes binding LOI to acquire TELI Pharmaceuticals

2025-10-21T11:45:13.000Z - 7 months ago

Telomir Pharmaceuticals executes binding LOI to acquire TELI Pharmaceuticals

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Oct 21, 2025, 7:30 AM EDT - 7 months ago

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Telomir Pharmaceuticals announces new laboratory findings on Telomir-1

2025-10-14T12:41:32.000Z - 7 months ago

Telomir Pharmaceuticals announces new laboratory findings on Telomir-1

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

Telomir says Telomir-1 selectively kills agressive TNBC cells

2025-10-09T11:40:49.000Z - 7 months ago

Telomir says Telomir-1 selectively kills agressive TNBC cells

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

Oct 9, 2025, 7:30 AM EDT - 7 months ago

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

Telomir Pharmaceuticals announces new findings in prostate cancer model

2025-10-07T11:40:23.000Z - 7 months ago

Telomir Pharmaceuticals announces new findings in prostate cancer model

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

Oct 7, 2025, 7:30 AM EDT - 7 months ago

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

Telomir Pharmaceuticals announces in vitro data on Telomir-1

2025-09-18T12:30:34.000Z - 8 months ago

Telomir Pharmaceuticals announces in vitro data on Telomir-1

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

Sep 18, 2025, 8:00 AM EDT - 8 months ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

Telomir Pharmaceuticals announces preclinical cancer data on Telomir-1

2025-09-09T12:30:34.000Z - 8 months ago

Telomir Pharmaceuticals announces preclinical cancer data on Telomir-1

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

Sep 9, 2025, 8:00 AM EDT - 8 months ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

Telomir Pharmaceuticals announces in vitro data on Telomir-1

2025-08-28T12:20:55.000Z - 9 months ago

Telomir Pharmaceuticals announces in vitro data on Telomir-1

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

Jul 24, 2025, 8:00 AM EDT - 10 months ago

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Jul 18, 2025, 8:00 AM EDT - 10 months ago

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Jun 18, 2025, 9:15 AM EDT - 11 months ago

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Jun 11, 2025, 9:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Jun 5, 2025, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 29, 2025, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 21, 2025, 9:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

May 15, 2025, 8:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

May 7, 2025, 8:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Feb 26, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Feb 21, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Feb 18, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Jan 28, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Jan 7, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Dec 23, 2024, 7:30 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Dec 12, 2024, 8:30 AM EST - 1 year ago

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Dec 3, 2024, 7:30 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Nov 21, 2024, 7:00 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Sep 26, 2024, 4:00 PM EDT - 1 year ago

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Aug 20, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Jul 2, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Jun 17, 2024, 4:10 PM EDT - 2 years ago

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

May 30, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Apr 16, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Mar 29, 2024, 4:44 PM EDT - 2 years ago

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

PF_Goodrich
PF_Goodrich May. 12 at 6:03 PM
$TELO tempted to buy more at this price but I already bought a bunch at 1.28
0 · Reply
Tristan2024
Tristan2024 May. 12 at 12:28 PM
$TELO 🚀🚀🚀
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:28 AM
$TELO do it and surprise everyone
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:28 AM
$TELO not regretted buying it for a second
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:28 AM
$TELO we will do it...one of a kind drug
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:27 AM
$TELO 2.5>4>6.4>8$
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:27 AM
$TELO never lost hope in that
0 · Reply
MarketAttack
MarketAttack May. 11 at 6:26 AM
$TELO news pending...watch the next jump to 2$
1 · Reply
Washingtonstate
Washingtonstate May. 9 at 1:46 AM
$TELO
1 · Reply
PF_Goodrich
PF_Goodrich May. 7 at 3:15 PM
$TELO come down to papa. my position is at 1.33 and im looking to build
0 · Reply
Tristan2024
Tristan2024 May. 7 at 11:25 AM
$TELO news this morning
0 · Reply
Tristan2024
Tristan2024 May. 6 at 12:19 PM
$TELO
0 · Reply
Tristan2024
Tristan2024 May. 4 at 3:44 PM
$TELO $8 by Friday, consolidating.
1 · Reply
Lupus_Leoque_Holdings
Lupus_Leoque_Holdings May. 1 at 8:02 PM
$SENS $BSWGF $TELO
0 · Reply
Lupus_Leoque_Holdings
Lupus_Leoque_Holdings May. 1 at 7:45 PM
$TELO Buy-in average under $1.50 ($1.39747)
0 · Reply
RaphaelRapoport
RaphaelRapoport May. 1 at 1:58 PM
$TELO does this company need to dilute?
1 · Reply
ACBigpapa1969
ACBigpapa1969 Apr. 30 at 9:55 PM
$TELO what a pos this has turned out to be 😆
1 · Reply
MarketAttack
MarketAttack Apr. 30 at 4:07 PM
$TELO do it now don't give them the chance to cover
0 · Reply
MarketAttack
MarketAttack Apr. 30 at 4:06 PM
$TELO squeeze the shorts hard...1.9 mil shares shorted
0 · Reply
YoullShortYourEyeOut
YoullShortYourEyeOut Apr. 30 at 2:50 PM
$TELO Love the volume here. Like a snake coiling to STRIKE!
3 · Reply
MarketAttack
MarketAttack Apr. 30 at 2:42 PM
$TELO huge barrier of entry to opponents
0 · Reply
MarketAttack
MarketAttack Apr. 30 at 2:40 PM
$TELO miracle drug
0 · Reply